- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About Royalty Pharma
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.
13.35%
1.42%
Stock Analysis
last close
$40.51
1-mo return
-8.1%
3-mo return
2.8%
avg daily vol.
2.36M
52-week high
47.1
52-week low
34.86
market cap.
$17.4B
forward pe
13.5
annual div.
0.76
roe
11.3%
ltg forecast
11.2%
dividend yield
1.88%
annual rev.
$2.3B
inst own.
64.3%
